In situ maturation of cultured pancreatic stem cells having a specified, intermediate stage of development
First Claim
Patent Images
1. A method of providing insulin to a mammal comprising the steps of:
- (a) encapsulating a cell culture of propagating pancreatic cells having the following properties;
(i) the cells have the ability to be passed from one culture vessel to a second vessel at an initial concentration of about 180 cells per square centimeter and expanded to about 1,800 cells per square centimeter;
(ii) both the unexpanded and expanded cells are 90% PDX-1 positive and have an insulin;
actin mRNA ratio of between 1;
100 and 1000;
1; and
(iii) the cells mature into an aggregate of cells, comprising an encapsulating mantle of CK19-positive cells and an inner cell mass, wherein the aggregate comprises 50–
5000 pancreatic cells and has a diameter of between 50 and 300 microns; and
,(b) inserting the encapsulated cells into the mammal, whereby the encapsulated cells further mature to insulin secreting cells and provide insulin to the mammal.
4 Assignments
0 Petitions
Accused Products
Abstract
This invention relates to the discovery that an intermediate, differentiated stage of pancreatic stem cells exist that can be matured in situ into a stable cell line that produces insulin in response to glucose. These cells are advantageous in that they are both expandable and stable in culture. This invention avoids the step of culturing the intermediate stage stem cells into later stage pancreatic cells.
-
Citations
4 Claims
-
1. A method of providing insulin to a mammal comprising the steps of:
-
(a) encapsulating a cell culture of propagating pancreatic cells having the following properties;
(i) the cells have the ability to be passed from one culture vessel to a second vessel at an initial concentration of about 180 cells per square centimeter and expanded to about 1,800 cells per square centimeter;
(ii) both the unexpanded and expanded cells are 90% PDX-1 positive and have an insulin;
actin mRNA ratio of between 1;
100 and 1000;
1; and
(iii) the cells mature into an aggregate of cells, comprising an encapsulating mantle of CK19-positive cells and an inner cell mass, wherein the aggregate comprises 50–
5000 pancreatic cells and has a diameter of between 50 and 300 microns; and
,(b) inserting the encapsulated cells into the mammal, whereby the encapsulated cells further mature to insulin secreting cells and provide insulin to the mammal. - View Dependent Claims (2, 3, 4)
-
Specification